Status:
COMPLETED
Study of Acetyllevocarnitine Hydrochloride Tablets in Chinese Patients With Paresthesias Caused by DPN
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.
Conditions:
Diabetic Peripheral Neuropathy (DPN)
Paresthesia
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy of Acetyllevocarnitine Hydrochloride Tablets compared with placebo after 24 weeks, in chinese patients with paresthesia caused by Diabetic Periphera...
Detailed Description
This 24-week, multicentre, randomised, double-blind, placebo-controlled phase III study is to assess the efficacy and safety of Acetyllevocarnitine Hydrochloride Tablets in Chinese patients with pares...
Eligibility Criteria
Inclusion
- Age ≥ 18 and ≤ 70 years, Male and female patients;
- Type 1 or 2 diabetes mellitus on hypoglycemic therapy for 3 months or more, and clinical diagnosis of DPN;
- HbA1c \< 9.0%;
- Toronto Clinical Neuropathy Score ≥ 6 at screening and baseline.
Exclusion
- Peripheral neuropathy caused by other diseases;
- History of acute complications of diabetes within the past 6 months, such as diabetic ketoacidosis, diabetic hyperosmolar hyperglycemia syndrome or lactic acidosis, etc.;
- Severe peripheral arterial disease; severe cardiopulmonary disease; or have a history of myocardial infarction, cerebrovascular accident or transient ischemic attack within 6 months before enrollment; or uncontrolled asthma or shortness of breath 2 months before enrollment; World Health Organization (WHO) cardiac function class III-IV; systolic blood pressure \>160 mmHg or diastolic blood pressure \>90 mmHg at screening;
- Any infection at the screening visit that is not suitable for study participation;
- Aspartate Transaminase (AST) or Alanine Transaminase (ALT) or total bilirubin or creatinine \> 2 times Upper Limit of Normal (ULN);
- Known allergy to L-carnitine ingredients;
- Severe systemic or psychiatric illness, history of epilepsy;
- History of malignancy or antitumor therapy;
- Severe bleeding disorder;
- Clinically significant abnormalities in thyroid function tests;
- Triglyceride \>5.6 mmol/L;
- Change of 2 points or more in the same item in mTCNS;
- Nursing or pregnant women.
Key Trial Info
Start Date :
July 23 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 25 2022
Estimated Enrollment :
516 Patients enrolled
Trial Details
Trial ID
NCT05319275
Start Date
July 23 2020
End Date
January 25 2022
Last Update
April 8 2022
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
2
Huizhou Central People's Hospital
Huizhou, Guangdong, China
3
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China
4
Hainan Third People's Hospital
Sanya, Hainan, China